Intervention Review

You have free access to this content

Interventions for erythema nodosum leprosum

  1. Natasja HJ Van Veen1,*,
  2. Diana NJ Lockwood2,
  3. Wim H van Brakel3,
  4. Jose Ramirez Jr4,
  5. Jan Hendrik Richardus1

Editorial Group: Cochrane Skin Group

Published Online: 8 JUL 2009

Assessed as up-to-date: 10 MAR 2009

DOI: 10.1002/14651858.CD006949.pub2

Database Title

Additional Information

How to Cite

Van Veen NHJ, Lockwood DNJ, van Brakel WH, Ramirez Jr J, Richardus JH. Interventions for erythema nodosum leprosum. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD006949. DOI: 10.1002/14651858.CD006949.pub2.

Author Information

  1. 1

    Erasmus MC, University Medical Center Rotterdam, Department of Public Health, Rotterdam, Netherlands

  2. 2

    London School of Hygiene & Tropical Medicine, Department of Infectious Diseases, London, UK

  3. 3

    Royal Tropical Institute, Leprosy Unit, Amsterdam, Netherlands

  4. 4

    University of Nottingham, c/o Cochrane Skin Group, Nottingham, UK

*Natasja HJ Van Veen, Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, Rotterdam, 3000 CA, Netherlands. n.vanveen@erasmusmc.nl.

Publication History

  1. Publication Status: New
  2. Published Online: 8 JUL 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (62K)Standard (453K)Full (542K)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Thalidomide versus aspirin, Outcome 1 Remission of skin lesions.
[Analysis 2.1]
Analysis 2.1. Comparison 2 100 mg thalidomide versus 300 mg thalidomide, Outcome 1 Remission of skin lesions.
[Analysis 2.2]
Analysis 2.2. Comparison 2 100 mg thalidomide versus 300 mg thalidomide, Outcome 2 Change in ENL severity (proportion improved).
[Analysis 2.3]
Analysis 2.3. Comparison 2 100 mg thalidomide versus 300 mg thalidomide, Outcome 3 Time to next clinical ENL episode.
[Analysis 2.4]
Analysis 2.4. Comparison 2 100 mg thalidomide versus 300 mg thalidomide, Outcome 4 Adverse effects.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Pentoxifylline versus thalidomide, Outcome 1 Remission of skin lesions.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Clofazimine versus prednisolone, Outcome 1 Remission of skin lesions.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Clofazimine versus prednisolone, Outcome 2 Time to next clinical ENL episode.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Clofazimine versus prednisolone, Outcome 3 Adverse effects.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Clofazimine versus thalidomide, Outcome 1 Time to next clinical ENL episode.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Indomethacin versus prednisolone, Outcome 1 Remission of skin lesions.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Indomethacin versus prednisolone, Outcome 2 Change in ENL severity (proportion improved).
[Analysis 6.3]
Analysis 6.3. Comparison 6 Indomethacin versus prednisolone, Outcome 3 Time to next clinical ENL episode.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Indomethacin versus prednisolone, Outcome 4 Adverse effects.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Indomethacin versus chloroquine, Outcome 1 Change in ENL severity (proportion improved).
[Analysis 7.2]
Analysis 7.2. Comparison 7 Indomethacin versus chloroquine, Outcome 2 Time to next clinical ENL episode.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Indomethacin versus chloroquine, Outcome 3 Adverse effects.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Indomethacin versus aspirin, Outcome 1 Change in ENL severity (proportion improved).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Indomethacin versus aspirin, Outcome 2 Time to next clinical ENL episode.
[Analysis 8.3]
Analysis 8.3. Comparison 8 Indomethacin versus aspirin, Outcome 3 Adverse effects.
[Analysis 9.1]
Analysis 9.1. Comparison 9 Levamisole versus placebo, Outcome 1 Change in ENL severity (proportion improved).
View Full Article (HTML) Summary (62K)Standard (453K)Full (542K)